Home Cart 0 Sign in  
X

[ CAS No. 13726-69-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 13726-69-7
Chemical Structure| 13726-69-7
Chemical Structure| 13726-69-7
Structure of 13726-69-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 13726-69-7 ]

Related Doc. of [ 13726-69-7 ]

Alternatived Products of [ 13726-69-7 ]

Product Details of [ 13726-69-7 ]

CAS No. :13726-69-7 MDL No. :MFCD00053370
Formula : C10H17NO5 Boiling Point : -
Linear Structure Formula :- InChI Key :BENKAPCDIOILGV-RQJHMYQMSA-N
M.W : 231.25 Pubchem ID :88804
Synonyms :

Calculated chemistry of [ 13726-69-7 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.8
Num. rotatable bonds : 4
Num. H-bond acceptors : 5.0
Num. H-bond donors : 2.0
Molar Refractivity : 59.53
TPSA : 87.07 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.53 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.69
Log Po/w (XLOGP3) : 0.25
Log Po/w (WLOGP) : 0.06
Log Po/w (MLOGP) : -0.07
Log Po/w (SILICOS-IT) : -0.64
Consensus Log Po/w : 0.26

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -1.17
Solubility : 15.7 mg/ml ; 0.068 mol/l
Class : Very soluble
Log S (Ali) : -1.64
Solubility : 5.31 mg/ml ; 0.023 mol/l
Class : Very soluble
Log S (SILICOS-IT) : 0.43
Solubility : 621.0 mg/ml ; 2.69 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.14

Safety of [ 13726-69-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 13726-69-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 13726-69-7 ]
  • Downstream synthetic route of [ 13726-69-7 ]

[ 13726-69-7 ] Synthesis Path-Upstream   1~29

  • 1
  • [ 13726-69-7 ]
  • [ 75-03-6 ]
  • [ 37813-30-2 ]
YieldReaction ConditionsOperation in experiment
91% With potassium carbonate In DMF (N,N-dimethyl-formamide) at 0 - 20℃; for 12 h; To a mixture of commercial (4R)-4-hydroxy-L-proline (75g, 0. 57MOL) in 10percent NAOH (11) was added (Boc) 20 (186g, 0. 855mol) at 0 C with stirring. The reaction was allowed to stir at RT for 10h and then washed with petroleum ether. The aqueous layer was acidified with citric acid to pH=4 and extracted with ethyl acetate. The combined organic layer was washed with brine and dried over NA2S04. The solvent was removed under vacuum to give crude (4R)-I-(TERT-BUTOXYCARBONYL)-4-HYDROXY-L-PROLINE (118G) as viscous liquid. Yield: 89percent To a solution of (4R)-1-(tert-butoxycarbonylo)-4-hydroxy-L-proline (100g, 0. 432MOL) in dry DMF (600ML), at 0 C was added K2CO3 (179g, 1. 3mol) followed by iodoethane (LOLG, 0. 65MOL). After stirring at RT for 12h, K2CO3 was filtered off and DMF was distilled off under reduce pressure. The residue was diluted with dichloromethane (11), washed with brine and dried. The solvent was removed under vacuum to give crude 1-1-TERT-BUTYL 2- ethyl (2S, 4R)-4-hydroxypyrrolidine-1, 2-dicarboxylate (103g) as yellow liquid. Yield: 91percent H NMR (300MHZ, CDC ) : 1.25 (t, 3H), 1.4 (d, 9H), 1.9-2. 2 (M, 2H), 2.5 (M, IH), 3.5 (M, 2H), 4.2 (M, 2H), 4.4-4. 6 (M, 2H). To a solution of 1-tert-butyl 2-ethyl (2S, 4R)-4-HYDROXYPYRROLIDINE-1, 2-dicarboxylate (100g, 0. 38MOL) in dry dichloromethane (1.51) at 25 C was added DMAP (47g, 0. 38MOL), followed by triethylamine (39g, 0. 38mol). To the above reaction mixture was added TBDMSCl (64g, 0. 42mol) dissolved in dry dichloromethane (200ML) drop-wise over a period OF 45MIN. After stirring at RT for 20H, the reaction mixture was diluted with water and separated the organic layer. The organic layer was washed with 5percent aq. citric acid, brine and dried over NA2SO4. The solvent was removed under vacuum to give I-TERT-BUTYL 2-ethyl (2S, 4R)-4- [TERT-BUTYL (DIMETHYL) silyl] oxy} pyrrolidine-1, 2-DICARBOXYLATE (140g) as a colorless liquid. Yield: 97percent 'H NMR (300MHz, CDC13) : 0.0 (s, 6H), 0. 8 (s, 9H), 1.2 (t, 3H), 1. 45 (d, 9H), 1. 7-1. 9 (M, 2H), 2.2 (M, 1H), 3.3-3. 5 (M, 2H), 4.2 (M, 2H), 4.5 (M, 1H). To a suspension of lithium aluminium hydride (lOg) in dry tetrahydrofuran (750ml) at- 40 C was added 1-tert-butyl 2-ethyl 1-TERT-BUTYL 2-ethyl (2S,4R)-4-[(tert- butyl (dimethyl) silyl] oxy} pyrrolidine-1, 2-dicarboxylate (100g, 0. 289mol) drop-wise in tetrahydrofuran (250ML). After stirring AT-TO C for 5H, the reaction mixture was quenched with 10percent NAOH (40ML). Filtered off the solid residue, washed with tetrahydrofuran and the filtrate was evaporated under reduce pressure to give tert-butyl (2S, 4R)-4-[TERT- butyl (dimethyl) silyl] OXY}-2- (HYDROXYMETHYL) PYRROLIDINE-1-CARBOXYLATE (85g) as a colorless liquid. Yield: 94percent LCMS: ESI+: 232 (M-Boc+H)+, 276 (M-tBu+H) +, 354 (M+Na) + 'H NMR (300MHZ, DMSO-d6) : 0.05 (s, 6H), 0.78 (s, 9H), 1.33 (s, 9H), 1.65-2. 00 (m, 2H), 3.20 (m, 2H), 3. 38 (m, 2H), 3.70 (m, 1H), 4.30 (m, 1H), 4. 60 (t, 1H). To a mixture of DMSO (53g, 0. 68MOL) and oxalylchloride (43G, 0. 34MOL) in dry dichloromethane (1. 51) at-78oC was added tert-butyl (2S, 4R)-4-[tert-butyl (dimethyl) silyl] OXY}-2-(HYDROXYMETHYL) PYLROLIDINE-L-CARBOXYLATE (75g, 0. 226MOL) drop-wise. After stirring at-78oC for IH, was added triethylamine (158ml, 1. 13MOL) drop-wise and warmed the reaction mixture slowly to RT. The reaction mixture was diluted with water and separated the organic layer. The organic layer was washed with brine and dried. The solvent was removed under vacuum to give tert-butyl (2S,4R)-4-[tert-butyl(dimethyl)silyl] OXY}-2-FORMYLPYRROLIDINE-L-CARBOXYLATE (70g) as pale yellow liquid. Yield: 94 percent
Reference: [1] Patent: WO2004/76407, 2004, A2, . Location in patent: Page 27-29
[2] Journal of Medicinal Chemistry, 2018, vol. 61, # 9, p. 4030 - 4051
  • 2
  • [ 64-17-5 ]
  • [ 13726-69-7 ]
  • [ 37813-30-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 14, p. 1511 - 1514
[2] Patent: US2005/165065, 2005, A1, . Location in patent: Page/Page column 21
  • 3
  • [ 74-96-4 ]
  • [ 13726-69-7 ]
  • [ 37813-30-2 ]
Reference: [1] Chemistry Letters, 2006, vol. 35, # 3, p. 300 - 301
[2] Chemistry Letters, 2001, # 7, p. 634 - 635
  • 4
  • [ 67-56-1 ]
  • [ 13726-69-7 ]
  • [ 40216-83-9 ]
YieldReaction ConditionsOperation in experiment
99% at 20℃; for 12 h; Compound 20r (2 g, 8.6 mmol) was taken up with a solution of HC1 (g) in methanol (4 M, 40 mL). The mixture was stirred at ambient temperature for 12 hrs. After that, the reaction mixture was concentrated under reduced pressure to afford compound 20s (1.6 g, yield 99percent) as a white solid.
Reference: [1] Patent: WO2012/37259, 2012, A1, . Location in patent: Page/Page column 74
  • 5
  • [ 13726-69-7 ]
  • [ 61478-26-0 ]
YieldReaction ConditionsOperation in experiment
96%
Stage #1: With borane-THF In tetrahydrofuran at 0 - 20℃; for 4.25 h;
Stage #2: With methanol In tetrahydrofuran at 20℃; for 62 h;
54 mL (54.0 mmol) borane-THF complex are added dropwise to a solution, cooled to 0° C., of 5.0 g (21.62 mmol) 1-tert-butyl (2S,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxylate in 25 mL dry THF, the reaction mixture is stirred for a further 15 min at 0° C. and then for 4 h at RT. While cooling with ice 60 mL MeOH are added, the mixture is stirred for a further 62 h at RT and then evaporated down i.vac. The residue obtained is purified by chromatography (silica gel, EtOAc/MeOH 19:1). Yield: 4.53 g (96percent of theoretical) C10H19NO4 (M=217.262) Calc.: molpeak (M+H)+: 218 Found: molpeak (M+H)+: 218 Rf value: 0.50 (silica gel, EtOAc/MeOH 19:1)
96% at 0℃; for 1 h; Inert atmosphere 4-hydroxyproline 36 (5.00 g, 21.6 mmol) was purged with N2and cooled on ice to 0 °C. BH3*THF (1 M solution, 64.9 mL,64.9 mmol) was added dropwise and the solution was stirred for1 h at 0 °C. When complete, the excess BH3*THF was quenched bycareful addition of water (60 mL). The mixture was extracted withbrine and EtOAc (3 100 mL), the combined organic layers weredried over Na2SO4, filtered an concentrated in vacuo. FCC (CH2Cl2/MeOH 92:8) gave the title compound as a thick colorless oil in 96percentyield. 1H NMR (300 MHz, 80 °C, DMSO-d6) d ppm 1.40 (s, 9 H)1.74-1.87 (m, 1 H) 1.89-2.01 (m, 1 H) 3.09 (br. s, 1 H) 3.17-3.31 (m,2 H) 3.40 (app. dd, J 10.5, 5.9 Hz, 1 H) 3.48 (app. dd, J 10.5,3.8 Hz,1 H) 3.74-3.84 (m,1 H) 4.22 (app. dt, J 9.2, 4.5 Hz,1 H) 4.46(br. s, 1 H). 13C NMR (75 MHz, 80 °C, DMSO-d6) d ppm 27.9, 36.7,54.6, 57.2, 62.2, 67.7, 77.8, carbonyl peak missing, even at 80 C.HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C10H20NO4 218.13868;Found 218.1390.
65% With lithium borohydride; chloro-trimethyl-silane In tetrahydrofuran at 0 - 20℃; Example 1
(2S,4R)-tert-butyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate.
To a 0° C. suspension of LiBH4 (2.0 equiv) in THF (0.67 M) was slowly added TMSCl (4.0 equiv) by syringe.
After stirring at room temperature for 30 minutes, (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (1.0 equiv) was then added, and the resulting mixture was stirred at room temperature overnight.
The reaction was quenched by the careful addition of sat'd.
aq. NaHCO3, and the mixture was diluted with EtOAc, and the organice layer was washed twice with sat'd.
aq. NaHCO3, once with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
The title compound was isolated in 65percent yield and used without further purification.
42.62% With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; for 0.2 h; To a stirred suspension of LiAlH4(2.95 g, 77.63 mmol) in dry THF (30 ml), was slowly added a solution of (2S,4R)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2- carboxylic acid (12.0 g, 51.92 mmol) in THF (150 ml) at 0 °C. After addition, the reaction mixture was then brought to room temperature and stirred for about 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched by the sequential addition of 3 mL of H20, 9 mL of 15percent aq. NaOH and 9 mL of H20. The mixture was then poured into EtOAc (150 ml) and stirred for about 30 minutes. The insoluble material was removed by filtration through celite, the solvent was removed from the filtrate by rotary evaporation and dried over Na2S04. The product was isolated by flash column chromatography on silica gel using EtOAc: hexane (4:6) as an eluent to give the desired product (4.8 g, yield: 42.62percent) as a thick oil. 1H NMR (300 MHz, DMSO-d6): δ 4.84-4.81 (m, 1H), 4.68-4.62 (m, 1H), 4.23-4.17 (m, 1H), 3.74 (m, 1H), 3.49-3.39 (m, 2H), 3.23-3.17 (m, 2H), 1.99-1.79 (m, 2H), 1.38 (s, 9H).

Reference: [1] Patent: US2005/239826, 2005, A1, . Location in patent: Page/Page column 27
[2] Patent: WO2005/103031, 2005, A1, . Location in patent: Page/Page column 70-71
[3] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 757 - 770
[4] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1989, vol. 28, # 1-11, p. 294 - 296
[5] Synthesis, 1990, vol. 1, # 10, p. 925 - 930
[6] Patent: US2007/66626, 2007, A1, . Location in patent: Page/Page column 22
[7] Patent: WO2017/17630, 2017, A1, . Location in patent: Page/Page column 67-68
[8] European Journal of Organic Chemistry, 2004, # 21, p. 4492 - 4502
[9] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3923 - 3931
[10] Journal of Medicinal Chemistry, 1991, vol. 34, # 9, p. 2787 - 2797
[11] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 10, p. 969 - 973
[12] Patent: US2017/749, 2017, A1,
  • 6
  • [ 13726-69-7 ]
  • [ 74-88-4 ]
  • [ 74844-91-0 ]
YieldReaction ConditionsOperation in experiment
95% With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 5 h; Step B: methyl r2S.4RVl-Boc-4-hvdroxypyrrolidine-2-carboxylate; [435] To a solution of (4R)-l-Boc-4-hydroxy-L-proline (8 g, 34.63 mmol) prepared in StepA in DMF was added K CO (14 g, lOlmmol) and methyliodide (2.6 ml, 51.9 mmol).The reaction mixture was stirred at rt for 5 h, concentrated in vacuo, and extracted withEtOAc. The organic extracts were washed with water and brine, dried over MgSO 4 , filtered, and concentrated in vacuo to give the title compound (8.0 g, 95 percent).[436] MS[M+H] = 246(M+1)
95% With potassium carbonate In N,N-dimethyl-formamide at 0 - 20℃; Step B:
Methyl(2S,4R)-1-Boc-4-hydroxypyrrolidine-2-carboxylate
(4R)-1-Boc-4-hydroxy-L-proline (8 g, 34.63 mmol) obtained in the Step A was dissolved in DMF (80 ml) and K2CO3 (14 g, 101 mmol) was added thereto, and methyl iodide (2.6 ml, 51.9 mmol) was added dropwise at 0° C.
The reaction mixture was stirred at room temperature for 5 hours, concentrated in vacuo, and extracted with EtOAc.
The organic extracts were washed with water and brine, dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (8.0 g, 95percent).
MS[M+H]=246 (M+1)
94.4% With potassium carbonate In N,N-dimethyl-formamide at 0 - 20℃; To a solution of compound 223-Si (10 g, 43.7 mmol) in DMF (100 mL) was added K2C03 (18.1 g, 131.3 mmol) followed by Mel (9.31 g, 65.6 mmol) at 0°C and the reaction was stirred atroom temperature overnight. The mixture was diluted with EtOAc and washed with 10percent aqueousLiC1 solution and brine, dried over Na2SO4, and concentrated under reduced pressure. The residuewas purified by chromatography on silica gel (eluted with petroleum ether: ethyl acetate = 5: 1 to2: 1) to afford compound 223-S2 (10.1 g, 94.4percent yield) as white solid. LC/MS (ESI) m/z: 246(M+H) .
60% With caesium carbonate In N,N-dimethyl-formamideInert atmosphere Boc-Hyp-OH (5.0 g, 21.6 mmol) was dissolved in dry DMF (75 mL). Cs2CO3 (7.4 g, 22.7 mmol) was added, and the solution was left under magnetic stirring for 15 min. MeI (1.6 mL, 25.6 mmol) was added dropwise and the reaction mixture was left under stirring overnight, whereupon the reaction mixture was filtered through celite. The filtrate was poured into water (250 mL) and extracted with EtOAc (5 ' 120 mL). The combined organic phases were washed with sat. NaHCO3 (aq) (150 mL), brine (130 mL) and dried over Na2SO4. The solvent was removed under reduced pressure, and the yellow oil was purified by flash column chromatography on silica gel (EtOAc:heptane (3:1), Rf = 0.33, KMnO4 stain). The resulting oil was triturated with Et2O to give the title compound (3.2 g, 60percent) as a white solid, which was used in the next step without further purification. 1H NMR (300 MHz, DMSO-d6) d 5.12 and 5.09 (2 ' s, 1H), 4.23-4.17 (m, 2H), 3.65 and 3.62 (2 ' s, 3H), 3.43-3.24 (m, 1H), 2.16-2.06 (m, 1H), 1.94-1.82 (m, 1H), 1.39 and 1.32 (2 ' s, 9H), rotamers; 13C NMR (75 MHz, DMSO-d6) d 175.3, 175.0, 156.3, 155.8, 81.7, 81.5, 70.7, 70.0, 59.4, 59.0, 55.9, 55.6, 52.6, 40.0, 39.3, 28.7, 28.6, rotamers; MS (ESI) calcd for C11H18NO5 [M - H]- 244.1 found 244.1; HRMS (ESI) calcd C11H20NO5 [M + H]+ 246.1346 found 246.1339; IR (neat) cm-1: 3437, 2989, 2954, 2882, 1738, 1659, 1420, 1197, 773, 573.
9.5 g
Stage #1: With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.25 h; Inert atmosphere
Stage #2: Inert atmosphere
A solution of trans-4-hydroxy-l-proline (5.24 g, 40 mmol) in THF (50 mL) and water (25 mL) was treated with aqueous NaOH (10percent, 17 mL) and di-tert-butyl dicarbonate (13.1 g, 60 mmol, 1.5 equiv). The mixture was stirred overnight at room temperature. THF was evaporated under reduced pressure. The aqueous solution was adjusted to pH 2 with 10percent aqueous NaHSO4 solution and extracted with EtOAc (3 .x. 50 mL). The combined organic phase was washed, dried and concentrated to yield the crude product, which was used in the next step without further purification.CommentTo a solution of the above mentioned crude product in DMF (180 mL) at room temperature was added Cs2CO3 (18.5 g, 56.8 mmol). After the mixture was stirred for 15 min, MeI (4.05 mL, 59.4 mmol) was added dropwise. The resulting mixture was then stirred overnight and filtered through a short column packed with Celite.(R).. The filtrate was concentrated under reduced pressure and the residue was partitioned between saturated aqueous NaHCO3 solution (50 mL) and EtOAc (50 mL). The aqueous phase was further extracted with EtOAc (2 .x. 50 mL). The combined organic layers were washed, dried and concentrated. Column chromatography (50percent EtOAc in hexanes) afforded the title compound as a yellowish oil (9.5 g, 97percent for two steps). -69.4 (c 1.3, MeOH); 1H NMR (400 MHz) δ 4.48 (s, 1H), 4.44 (t, J = 7.7 Hz, 0.4H), 4.38 (t, J = 8.0 Hz, 0.6H), 3.72 (d, J = 4.7 Hz, 3H), 3.61 (dt, J = 15.6, 7.8 Hz, 1H), 3.55 (d, J = 11.7 Hz, 0.6H), 3.44 (d, J = 11.3 Hz, 0.4H), 2.28 (m, 1.6H), 2.16 (s, 0.4H), 2.11-2.00 (m, 1H), 1.75 (s, 0.6H), 1.42 (m, 9H); 13C NMR (126 MHz) δ 173.73, 173.51, 154.61, 154.05, 80.47, 80.38, 77.36, 77.31, 77.11, 76.85, 70.31, 69.57, 57.98, 57.55, 54.84, 54.78, 52.35, 52.14, 39.21, 38.56, 28.46, 28.33, 0.07; HRMS (ESI) calcd for C11H20NO5m/z 246.1341 ([M+H]+), found m/z 246.1333.
10.5 g With potassium carbonate In N,N-dimethyl-formamide at 20℃; To a solution of compound 105 (10 g, 43.3 mmol) DMF (150 mL), was added K2C03 (12 g, 86.6 mmol) and Mel (6.1 g, 43.3 mmol). The resulting mixture was stirred at room temperature overnight. The crude mixture was diluted with water (500 mL), extracted with DCM (500 mL). The organic layer was dried over anhydrous Na2SC>4, filtered, and concentrated to dryness to give title compound 106, (2S,4R)-l-tert-butyl 2-methyl 4- hydroxypyrrolidine-l,2-dicarboxylate (10.5 g) without further purification. LC-MS (LC method 1): m/z 246 (M+l)+.

Reference: [1] Patent: WO2008/7930, 2008, A1, . Location in patent: Page/Page column 25
[2] Patent: US2010/120783, 2010, A1, . Location in patent: Page/Page column 10
[3] Organic Letters, 2015, vol. 17, # 18, p. 4620 - 4623
[4] Patent: WO2018/160889, 2018, A1, . Location in patent: Page/Page column 645; 646
[5] Chemistry - A European Journal, 2006, vol. 12, # 15, p. 4121 - 4143
[6] Organic Letters, 2016, vol. 18, # 24, p. 6292 - 6295
[7] Tetrahedron Letters, 2011, vol. 52, # 52, p. 7049 - 7053
[8] ACS Combinatorial Science, 2011, vol. 13, # 6, p. 667 - 675
[9] Patent: WO2005/87760, 2005, A1, . Location in patent: Page/Page column 19-20
[10] Patent: US5102877, 1992, A,
[11] Advanced Synthesis and Catalysis, 2011, vol. 353, # 1, p. 113 - 124
[12] Chimia, 2011, vol. 65, # 4, p. 264 - 267
[13] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 24, p. 7664 - 7678
[14] Patent: WO2017/189866, 2017, A1, . Location in patent: Paragraph 0184
  • 7
  • [ 13726-69-7 ]
  • [ 77-78-1 ]
  • [ 74844-91-0 ]
YieldReaction ConditionsOperation in experiment
93% With potassium carbonate In acetone for 2 h; Reflux Example 1 . Amino Acid Analogue Synthetic Approaches A. Synthesis of Fmoc-2S,4/R-perfluoro-tert-butyl-hydoxyproline (7)
Reference: [1] Patent: WO2014/127052, 2014, A1, . Location in patent: Page/Page column 10
[2] Journal of Fluorine Chemistry, 2008, vol. 129, # 9, p. 781 - 784
[3] Patent: WO2015/173779, 2015, A1, . Location in patent: Page/Page column 26
[4] Organic and Biomolecular Chemistry, 2016, vol. 14, # 7, p. 2327 - 2346
  • 8
  • [ 13726-69-7 ]
  • [ 18107-18-1 ]
  • [ 74844-91-0 ]
YieldReaction ConditionsOperation in experiment
100% at 0℃; for 1 h; To a stirred solution of (2S, 4R) -4-hydroxyproline (Aldrich) (25 g, [108] mmol) in methanol (50 mL) at [0 °C] was added [TRIMETHYLSILYLDIAZOMETHENE] (24.6 g, 216 mmol). The mixture was stirred at [0 °C FOR] 1 hour. The residue obtained on removal of solvent and purification by column chromatography using 50percent ethyl acetate in hexanes (27 g, 100percent) was used in the next step. To oxalyl chloride (15 g, 118 mmol) in DCM (15 mL) [AT-78 °C,] DMSO (18.6 mL, 236 mmol) was added slowly over 15 minutes. After the completion of addition, the above product (2S, [4R)-N-BOC-4-HYDROXYPROLINE] methylester (26.5 g, 108 mmol) in DCM (100 mL) was added at-78 °C for 20 minutes. Triethylamine (54.6 g, 540 mmol) was added followed by stirring at room temperature for 2 hours. The reaction mixture was then washed with 10percent aq [HC1] (200 mL) and the organic layer was separated and dried over sodium sulfate. The crude product obtained on removal of solvent was purified on silica gel column chromatography using 50percent EtoAc in hexanes to obtain (2S, 4R) -N-Boc-4-Ketoproline methylester (20 g, [78percent).] [[0477] 1H] NMR (300 MHz, [CDC13)] 8 4.80 (m, 1), 3.88 (d, [J=8.] 7,2), 3.77 (s, 3), 2.98 (m, 1), 2.58 (m, 1), 1.45 (s, [9) ;] MS (ES+): [244] [(M+1).] [[0478]] To a stirred solution of [(2S,] 4R) -N-Boc-4-Ketoproline methylester (1 g, 4.11 mmol) in THF (10 mL), tetraallyltin (1.08 mL, 4.52 mmol) in dry THF was added, then cooled to [0 °C] before borontrifluoride etherate (0.520 mL, 4.11 mmol) was added drop wise. The mixture was stirred at [0 °C] for lh and then at room temperature for an additional 2 hours. Potassium fluoride (360 mg in [5ML] water) and celite (1 g) was added and the reaction mixture was stirred for an hour. The reaction mixture was filtered and concentrated to dryness and the residue was dissolved in DCM (200 mL), washed with water [(LOOML)] and brine 100 mL), dried over [MGS04] and evaporated to dryness. T he residue obtained on removal of solvent was purified by silica gel column chromatography using 50percent EtOAc in hexanes to obtain 4-Hydroxy-4-allylproline methylester (0.94 g, 80percent). [[0479] 1H] NMR (300 MHz, [CDC13)] 8 5.87 (m, 1), 5.19 (m, 2), 4.34 (m, 1), 3.75 [(D,] [J=4.] 8, 3), 3.50 (m, 3), 2.37 (m, 1), 2.21 (m, 1), 1.39 (d, [J=12.] 9,9) ; MS (ES+): 308 [(M+23).] [[0480]] To a stirred solution of DAST (1.06 g, 6. [58] mmol) in DCM (10 mL) [AT-78 °C,] [4-HYDROXY-4-ALLYLPROLINE] methylester (940 mg, 3.3 mmol) in dry DCM (10 mL) was added slowly. The mixture was then stirred at-78 °C for [LH,] then at-10 °C for an additional [LH.] DCM (50 mL) was added, quenched with [NH4C1] [(10percent,] 150 mL) and the organic layer was separated, dried over sodium sulfate and evaporated to dryness. The residue obtained on removal of solvent was purified by silica gel column chromatography using 5percent EtOAc in hexanes as eluent to obtain [4-FLUORO-4-ALLYLPROLINE] methylester (330 mg, 34percent). [[0481] IH] NMR (300 MHz, [CDC113)] [AMP;] 5.82 (m, 1), 5.12 (m, 2), 4.43 (m, 1), 3.66 (s, 3), 3.47 (m, 1), 2.37 (m, 1), 2.43 (m, 4), 1.37 (dd, [J=4.] 5,13. 8, [9) ;] MS (ES+): [310 (M+23).] [[0482]] To a solution of 4-fluoro-4-allylproline methylester (0. [33] g, 1.15 mmol) in MeOH (15 mL) was added 10percent Pd/C (40 mg) and hydrogenated at 1 atmosphere. The catalyst was filtered through celite and washed with methanol. To the product obtained on removal of solvent (330 mg, 1.15 mmol) in THF (12 mL) was added aq lithium hydroxide monohydrate (60 mg, 1. [38] mmol). The reaction mixture was stirred at room temperature overnight. THF was removed and the residue was taken up in ethyl acetate (50 mL), washed with 10percent citric acid (100 mL) and brine (20 mL). Removal of solvent resulted in 4-fluoro-4-propylproline (310 mg, 100percent). [[0483] 1H] NMR [(300] MHz, CD30D) 8 4.43 (m, 1), 3.71 (m, 6), 2.51 (m, 2), 1.98 (m, 3), 1.45 (m, 9), 0.96 (m, 3); MS (ES-): 274 (M-1). [[0484]] To a solution of 4-fluoro-4-propylproline (310 mg, 1.15 mmol) in DMF (3 mL) at [0 °C,] 7-Methyl MTL 2b [(RL] =Me, R2=Me) (272 mg, 1.15 mmol), HBTU (469 [MG, L] 1.3 mmol) and DIEA (290 mg, 2.3 mmol) was added, left stirred at room temperature for 16 hours. DMF was removed and the residue obtained was purified by 3percent MeOH in DCM (40 mg, 93percent). The product from the column purification was taken in DCE (6 mL), to which triethylsilane (0.16 mL), TFA (2 mL) and water (0.16 mL) was added and stirred at room temperature for 1.5 hours. Removal of solvent followed by purification on silica gel column chromatography using 10percent MeOH in DCM resulted in the title compound as isomeric mixtures with lower RF fraction (160 mg, 50percent). [[0485] 1H] NMR (300 MHz, CD30D) 8 5.25 (d, [J=5.] 7, [1),] 4.46 (m, 1), 4.24 (dd, [J=5.] 7,10. 2, 1), 4.08 (m, 2), 3.81 [(D,] [J=2.] 4,1), 3.52 (m, 3), 2.73 (m, 1), 2.10 (m, 4), 1.88 (m, 2), 1.50 (m, 2), 0.99 [(T,] [J=7.] 5,3), 0.91 (dd, [J=3.] 0,6. 9,6) ; MS (ES+): 409 [(M+L) ;)] and higher Rf fraction (40 mg, [12percent). 1H] NMR (300 MHz, CD30D) [8] 5. [38 (D, J=5.] 4,1), 4.46 (m, 1), 4.24 (dd, [J=2.] 7,7. 2, 1), 4.08 (m, 2), 3.81 (d, [J=2.] 4,1), 3.64 (m, 3), 2.73 (m, 1), 2.11 (m, 4), 1.84 (m, 2), 1.47 (m, 2), 0.98 (t, [J=7.] 5,3), 0.91 (dd, [J=3.] 0,6. 9,6) ; MS (METHOD ES+): 409 [(M+1).]
Reference: [1] Patent: WO2004/16632, 2004, A2, . Location in patent: Page 124-126
[2] Journal of Organic Chemistry, 2005, vol. 70, # 9, p. 3353 - 3362
[3] Angewandte Chemie - International Edition, 2013, vol. 52, # 22, p. 5789 - 5794[4] Angew. Chem., 2013, vol. 125, # 22, p. 5901 - 5906,7
  • 9
  • [ 186581-53-3 ]
  • [ 13726-69-7 ]
  • [ 74844-91-0 ]
Reference: [1] Organic Letters, 2001, vol. 3, # 16, p. 2481 - 2484
[2] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 1, p. 251 - 259
[3] Patent: WO2008/55068, 2008, A2, . Location in patent: Page/Page column 179-180
[4] Patent: WO2009/137503, 2009, A1, . Location in patent: Page/Page column 60
[5] Patent: US2017/749, 2017, A1, . Location in patent: Paragraph 0569
[6] Journal of Medicinal Chemistry, 2003, vol. 46, # 20, p. 4322 - 4332
[7] Journal of Medicinal Chemistry, 1991, vol. 34, # 9, p. 2787 - 2797
  • 10
  • [ 13726-69-7 ]
  • [ 7529-22-8 ]
  • [ 102195-80-2 ]
Reference: [1] Patent: WO2008/51404, 2008, A2, . Location in patent: Page/Page column 106
  • 11
  • [ 13726-69-7 ]
  • [ 102195-80-2 ]
Reference: [1] Chemistry - A European Journal, 2006, vol. 12, # 15, p. 4121 - 4143
[2] Patent: WO2018/160889, 2018, A1,
  • 12
  • [ 13726-69-7 ]
  • [ 77449-94-6 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 1, p. 21 - 26
  • 13
  • [ 13726-69-7 ]
  • [ 51154-06-4 ]
Reference: [1] Synthesis, 2004, # 14, p. 2367 - 2375
  • 14
  • [ 100-39-0 ]
  • [ 13726-69-7 ]
  • [ 40350-83-2 ]
Reference: [1] European Journal of Organic Chemistry, 2014, vol. 2014, # 24, p. 5351 - 5355
[2] Organic and Biomolecular Chemistry, 2017, vol. 15, # 4, p. 894 - 910
[3] Tetrahedron, 1986, vol. 42, # 21, p. 6039 - 6045
[4] Journal of Medicinal Chemistry, 1988, vol. 31, # 4, p. 875 - 885
[5] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 9, p. 2151 - 2154
[6] Patent: US2015/202333, 2015, A1, . Location in patent: Paragraph 0060; 0061
  • 15
  • [ 13726-69-7 ]
  • [ 84348-37-8 ]
YieldReaction ConditionsOperation in experiment
95.9% With 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; trichloroisocyanuric acid In ethyl acetate at -5 - 30℃; for 1.33333 h; Trichloroisocyanuric acid (75.6 g) was added to a solution of (4R)-1-(tert- butoxycarbonyl)-4-hydroxy-L-proline (Formula IV, prepared according to the process of Example 1; 100 g) in ethyl acetate (1000 mL). The solution was cooled to 0°C to -5°C. A solution of TEMPO in ethyl acetate (3.38 g in 50 mL ethyl acetate) was slowly added to the reaction mixture at -5°C to 10°C, and the reaction mixture was stirred at the same temperature for 20 minutes. The reaction mixture was heated to a temperature of 25°C to 30°C, and stirred at the same temperature for 60 minutes. After completion of the reaction, the reaction mixture was quenched with deionized water (200 mL), and stirred for 60 minutes at a temperature of about 25°C to 30°C. The reaction mixture was filtered through a Hyflo® bed. The filtrate was washed with deionized water (2 x 200 mL). The layers were separated. The organic layer was washed with an aqueous solution of sodium chloride (prepared by adding 40 g sodium hydroxide to 200 mL deionized water). The organic layer was concentrated at a temperature of about 50°C under reduced pressure to obtain a residue. The residue was dissolved in ethyl acetate ( 100 mL). Hexanes (400 mL) were slowly added to the solution of ethyl acetate. The reaction mixture was stirred at 25°C to 30°C for 30 minutes. The reaction mixture was filtered to obtain a solid. The solid was washed with a mixture of ethyl acetate (20 mL) and hexanes (80 mL), and dried at 40°C to 45°C under reduced pressure to obtain 1-(tert-butoxycarbonyl)-4-oxo-L-proline. Yield: 95.9percent
76% With chromic acid In water; acetone at 25℃; for 0.75 h; Commercial (2S, 4R)-1- (tert-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid (30g, 0. [13MOL)] was dissolved in acetone (1500ml). A mechanical stirrer was placed in the flask and the solution stirred vigorously. A freshly made solution of 8N chromic acid was prepared by dissolving chromium trioxide (66.7g, 0. [667MOL)] in water [(40ML),] adding concentrated sulphuric acid (53. [3ML)] and adding enough water to bring the solution volume to 115ml. The 8N chromic acid solution [(115ML)] was then added dropwise over a period of 30 min with continued vigorous stirring, the reaction's exotherm being maintained at the optimal temperature of [25C] by the use of an ice bath. After the complete addition of the chromic acid, the reaction mixture was stirred for a further 15 minutes-maintaining the optimal temperature of [25C.] The reaction mixture was then quenched by the addition of methanol [(20ML).] Exotherm was controlled by the use of an ice bath and, if necessary, direct addition of a small amount of crushed ice to the reaction mixture itself. The reaction mixture was filtered through a Celite pad and then concentrated in vacuo. The resulting acidic solution was then extracted with ethyl acetate [(3X300ML)] and the combined organic layers washed with brine [(2XLOOML),] then dried with magnesium sulfate and concentrated in vacuo. The crude product was recrystallized from ethyl acetate to give a white crystalline product, [(25)-1-(TERT-BUTOXYCARBONYL)-4-OXO-2-PYRROLIDINECARBOXYLIC] acid (22. [55G,] 76percent) [(LA).] [(1H] NMR [(360MHZ,] [CDC13)] : 1.4 [(M,] 9H), 2.5-3. 0 (m, 2H), 3.7-3. 9 [(M,] 2H), 4.75 (dd, [1H)).]
67% at -3 - 20℃; To a 1 L reaction flask were added 60.0 g (0.26 mol) of N-Boc-L-hydroxyproline,(0.26 mol) of TCCA, stirred and cooled to room temperature,To the reaction flask was added 2.02 g (0.012 mol) of TEMPO (reaction exotherm) in portions,Control feeding rate,The temperature used in the -3 ° C, filtration, the filtrate was concentrated to a white solid 40.12g, yield 67percent.
62% With sodium hypochlorite; 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical In Isopropyl acetate at 0 - 20℃; Example 1. Preparation of (5 l -(fert-butoxycarbonyl)-4-oxopyrrolidine-2- carboxylic acidTo a solution of (2R, 45)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2- carboxylic acid (92 g, 0.398 mol) in isopropyl acetate (460 mL) was added TEMPO (2.49 g, 0.05 eq) at 0°C. A solution of NaCIO (12.5 wtpercent, 370 mL) was added dropwise to the reaction mixture while maintaining the temperature at 0-5°C. The reaction was slowly allowed to warm to room temperature and stirred at room temperature overnight. The organic layer was separated and the aqueous layer was treated with 1M KHSO4 solution and extracted with isopropyl acetate (2 x 150 mL). The combined organic layeres were washed with 5percent Na2S203 (100 mL), brine, dried (Na2S04), filtered and evaporated to provide the title compound as a solid. It was triturated with acetonitrile (40 mL), filtered and dried to give a white solid (52.3g). The filtrate was concentrated, treated with 50percent ethyl acetate in hexanes (20 mL) and stored in refrigerator for overnight before being filtered and dried to give a white solid (3.94 g). Totally obtained 56.24 g (62percent). 1H NMR (500 MHz, OMSO-d6): 12.99 (br s, 1H), 4.54-4.50 (m, 1H), 3.84-3.77 (m, 1H), 3.68-3.63 (m, 1H), 3.15-3.06 (m, 1H), -2.49 (m, 1H, overlapped with DMSO), 1.40 and 1.37 (2 s, 9H).
45% With sodium periodate In water; ethyl acetate at 35℃; 6 h To an ice cooled solution of Boc hydroxyproline 1 (20 g, 86.4 mmol) in ethyl acetate (300 ml_) were added a saturated aqueous solution of sodium metaperiodate (500 mL) and ruthenium oxide (115 mg, 0.864 mmol). The biphasic mixture was vigorously stirred at 350C for 6h and monitored by LC/MS. When all the starting material was converted to product, as visible on the ES' trace of the LC/MS, the two phases were allowed to separate. The aqueous layer was extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with water (200 mL) and brine (100 mL), dried over magnesium sulfate and concentrated in vacuo. The residue was triturated with diethyl ether, retrieved by filtration and recrystallised in acetonitrile to give pure colorless crystals of the desired product 2 (8.90 g, 45percent).Analytical Data: LC/MS 2.12 min (ES-) m/z (relative intensity) 228 [M- H]", 100).
38.1 g With 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; 18-crown-6 ether; sode de l'acide trichloroisocyanurique; sodium bromide In chloroform; water at 0 - 10℃; for 2 h; Transfer the above aqueous layer containing the intermediate carboxylate to another dry clean reaction bottle, then add 150 mL of chloroform, 0.55 g of TEMPO and 0.22 g of sodium bromide and 0.1 g of 18-crown-6-ether. Slowly reduce the temperature to 0 ° C under stirring, start to add 250 mL of aqueous solution of sodium dichloroisocyanurate with a mass concentration of 25percent, and control the temperature of the reaction system during the dropwise addition to 0 ° C ~ 10 ° C, continue after the completion of the dropwise addition. After the reaction was completed for 2.0 h, after the reaction was completed, the pH of the system was adjusted to 3 to 4 by adding a potassium bisulfate aqueous solution having a mass concentration of 25percent to carry out acidification. After the pH value was substantially stabilized in the range, the product was stirred and analyzed for 30 minutes. The crude product is obtained by suction filtration, and the crude product has a purity of 99percent. The crude product is added to 100 mL of water and beaten at room temperature for 30 min, filtered to obtain a wet product, and after drying, the final product is obtained.N-tert-butoxycarbonyl-keto-L-proline 38.1 g, purity 99.6percent, the total yield of the two steps reached 86.5percent.

Reference: [1] Patent: WO2015/19238, 2015, A1, . Location in patent: Page/Page column 9
[2] Journal of the American Chemical Society, 2017, vol. 139, # 17, p. 6152 - 6159
[3] Organic Process Research and Development, 2015, vol. 19, # 1, p. 270 - 283
[4] Patent: WO2004/5249, 2004, A1, . Location in patent: Page 30-31
[5] Tetrahedron Letters, 1993, vol. 34, # 46, p. 7489 - 7492
[6] Patent: CN105801462, 2016, A, . Location in patent: Paragraph 0052; 0053
[7] Patent: WO2012/158861, 2012, A2, . Location in patent: Page/Page column 18-19
[8] Arkivoc, 2011, vol. 2011, # 6, p. 130 - 136
[9] Journal of Organic Chemistry, 2001, vol. 66, # 10, p. 3593 - 3596
[10] Patent: WO2010/43877, 2010, A1, . Location in patent: Page/Page column 51
[11] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 7, p. 2253 - 2265
[12] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 1, p. 251 - 259
[13] Patent: WO2005/95340, 2005, A1, . Location in patent: Page/Page column 11-12
[14] Patent: WO2007/25307, 2007, A2, . Location in patent: Page/Page column 308-309
[15] Patent: WO2016/79699, 2016, A1, . Location in patent: Page/Page column 11 ; 12
[16] Patent: CN106543062, 2017, A, . Location in patent: Paragraph 0019-0020
[17] Patent: CN107954990, 2018, A, . Location in patent: Paragraph 0075; 0077; 0078; 0148; 0217
[18] Patent: CN108218755, 2018, A, . Location in patent: Paragraph 0018
[19] Patent: CN108440363, 2018, A, . Location in patent: Paragraph 0025; 0028; 0031; 0034; 0035; 0037; 0041;
[20] Patent: WO2008/106139, 2008, A1, . Location in patent: Page/Page column 478
  • 16
  • [ 7664-93-9 ]
  • [ 13726-69-7 ]
  • [ 84348-37-8 ]
YieldReaction ConditionsOperation in experiment
76% With chromic acid In water; acetone Intermediate 1: (2S)-1-(tert-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic Acid
Commercial (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid (30 g, 0.13 mol) was dissolved in acetone (1500 ml).
A mechanical stirrer was placed in the flask and the solution stirred vigorously.
A freshly made solution of 8N chromic acid was prepared by dissolving chromium trioxide (66.7 g, 0.667 mol) in water (40 ml), adding concentrated sulphuric acid (53.3 ml) and adding enough water to bring the solution volume to 115 ml.
The 8N chromic acid solution (115 ml) was then added dropwise over a period of 30 minutes with continued vigorous stirring, the reaction's exotherm being maintained at the optimal temperature of 25° C. by the use of an ice bath.
After the complete addition of the chromic acid, the reac-tion mixture was stirred for a further 15 minutes-maintaining the optimal temperature of 25° C.
The reaction mixture was then quenched by the addition of methanol (20ml).
Exotherm controlled by the use of an ice bath and, if necessary, direct addition of a small amount of crushed ice to the reaction mixture itself.
The reaction mixture was filtered through a Celite pad and then concentrated in vacuo.
The resulting acidic solution was then extracted with ethyl acetate (3*300 ml) and the combined organic layers washed with brine (2*100 ml).
Organics then dried with magnesium sulfate and concentrated in vacuo.
Crude product recrystallized from Ethyl acetate to give the white crystalline product, (2S)-1-(tertbutoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid (22.55 g, 76percent).
The antipodal intermediate, (2R)-1-(tert-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid, was made according to the same protocol, starting from commercial (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid.
1H NMR (360 MHz, CDCl3); 1.4 (m, 9H), 2.5-3.0 (m, 2H), 3.7-3.9 (m, 2H), 4.75 (dd, 1H)
76% With chromic acid In water; acetone Intermediate 1: (2S)-1-(tert-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic Acid
Commercial (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid (30 g, 0.13 mol) was dissolved in acetone (1500 ml).
A mechanical stirrer was placed in the flask and the solution stirred vigorously.
A freshly made solution of 8N chromic acid was prepared by dissolving chromium trioxide (66.7 g, 0.667 mol) in water (40 ml), adding concentrated sulphuric acid (53.3 ml) and adding enough water to bring the solution volume to 115 ml.
The 8N chromic acid solution (115 ml) was then added dropwise over a period of 30 minutes with continued vigorous stirring, the reaction's exotherm being maintained at the optimal temperature of 25° C. by the use of an ice bath.
After the complete addition of the chromic acid, the reac-tion mixture was stirred for a further 15 minutes-maintaining the optimal temperature of 25° C.
The reaction mixture was then quenched by the addition of methanol (20 ml).
Exotherm controlled by the use of an ice bath and, if necessary, direct addition of a small amount of crushed ice to the reaction mixture itself.
The reaction mixture was filtered through a Celite pad and then concentrated in vacuo.
The resulting acidic solution was then extracted with ethyl acetate (3*300 ml) and the combined organic layers washed with brine (2x100ll).
Organics then dried with magnesium sulfate and concentrated in vacuo.
Crude product recrystallized from ethyl acetate to give the white crystalline product, (2S)-1-(tert-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid (22.55 g, 76percent).
The antipodal intermediate, (2-R)-1-(tert-butoxycarbonyl)-4oxo-2-pyrrolidinecarboxylic acid, was made according to the same protocol, starting from commercial (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid.
1H NMR (360 MHz, CDCl3); 1.4 (m, 9H), 2.5-3.0 (m, 2H), 3.7-3.9 (m, 2H), 4.75 (dd, 111)
Reference: [1] Patent: US2003/171309, 2003, A1,
[2] Patent: US2003/212012, 2003, A1,
  • 17
  • [ 13726-69-7 ]
  • [ 84348-37-8 ]
Reference: [1] Patent: US2010/272681, 2010, A1,
  • 18
  • [ 13726-69-7 ]
  • [ 87691-27-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 7, p. 2253 - 2265
[2] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 1, p. 251 - 259
[3] Organic Letters, 2011, vol. 13, # 20, p. 5588 - 5591
  • 19
  • [ 13726-69-7 ]
  • [ 7529-22-8 ]
  • [ 166410-05-5 ]
YieldReaction ConditionsOperation in experiment
61% With tetrapropylammonium perruthennate In hexane; dichloromethane; ethyl acetate EXAMPLE 5 STR11 Step A: 1-(tert-Butyloxycarbonyl)-4-oxo-L-Proline tert-Butyl Ester
To a solution of (4R)-1-(tert-butyloxycarbonyl)-4-hydroxy-L-proline (1.0 g, 3.48 mmol) in dichloromethane (3 mL) was added 4-methylmorpholine N-oxide (612 mg, 5.22 mmol) followed by 4 A powdered molecular sieves (1.74 g) and tetrapropylammonium perruthenate(VII) (TPAP) (61 mg, 0.174 mmol).
After stirring for 1 hour at room temperature, an additional 30 mg of TPAP was added, and the reaction was continued for 2 hours.
The reaction mixture was applied to a column of silica gel (packed in 20percent ethyl acetate/hexane).
Elution with the same mobile phase afforded pure ketone as a white crystalline solid; yield 610 mg (61percent).
400 MHz 1 H-NMR (CDCl3): δ1.43 (s, 9H); 1.47 (s, 9H); 2.50 (dd, 1H); 2.89 (m, 1H); 3.82-3.93 (m, 2H); 4.60 (dd, 1H).
Reference: [1] Patent: US5821261, 1998, A,
  • 20
  • [ 13726-69-7 ]
  • [ 166410-05-5 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 10, p. 3593 - 3596
[2] Journal of Organic Chemistry, 2017, vol. 82, # 16, p. 8419 - 8425
  • 21
  • [ 13726-69-7 ]
  • [ 203866-13-1 ]
Reference: [1] Chemical Communications, 2018, vol. 54, # 70, p. 9749 - 9752
  • 22
  • [ 13726-69-7 ]
  • [ 203866-16-4 ]
Reference: [1] Chemical Communications, 2018, vol. 54, # 70, p. 9749 - 9752
  • 23
  • [ 13726-69-7 ]
  • [ 474417-79-3 ]
Reference: [1] Journal of Organic Chemistry, 2002, vol. 67, # 20, p. 7162 - 7164
  • 24
  • [ 13726-69-7 ]
  • [ 109384-24-9 ]
YieldReaction ConditionsOperation in experiment
86%
Stage #1: With chloroformic acid ethyl ester; triethylamine In tetrahydrofuran at -15℃; for 0.166667 h; Inert atmosphere
Stage #2: With ammonia In tetrahydrofuran; water at -15 - 5℃; for 2 h;
Step 2 Preparation of (2S,4R)-tert-butyl 2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate (2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 13b (86.4 g, 0.374 mol) was dissolved in 1.2 L of tetrahydrofuran followed by addition of triethylamine (41 g, 0.411 mol) under argon atmosphere. The reaction mixture was cooled to -15 °C, ethyl chlorformate (43.84 g, 0.411 mol) was added. After the mixture was stirred for 10 minutes, aqueous ammonia (236.8 mL) was added. The reaction mixture was slowly warmed up to 5 °C during 2 hours followed by addition of ammonium chloride (32 g). The reaction mixture was stirred for 30 minutes and separated. The separated organic phase was dried over anhydrous sodium sulfate, and the aqueous phase was extracted with ethyl acetate (100 mL.x.2). The combined organic extracts were concentrated under reduced pressure to obtain the title compound (2S,4R)-tert-butyl 2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate 13c (74 g, yield 86percent) as a white solid.
59%
Stage #1: With chloroformic acid ethyl ester; triethylamine In tetrahydrofuran at -10℃; for 1 h;
Stage #2: With ammonia In tetrahydrofuran; water at -5 - 20℃; for 2 h;
TERT-BUTYL 4R)-2-(AMINOCARBONYL)-4-HYDROXYPYRROLIDINE-1-CARBOXYLATE] with the general formula (VII), where Z means a group of formula (E) 36,32 g (157 mmol) of (2S, [4R)-L-(TERT-BUTOXYZARBONYL)-4-HYDROXY-PYRROLIDINE-2-] carboxylic acid [(ALDRICH)] was dissolved in 450 [ML] of tetrahydro-furane and to the solution 24 [ML] (172 mmol) of triethylamine was added. To the resulting mixture, at-10 C 16,3 ml (172 mmol) of ethyl chloroformate was added dropwise and at the same temperature it was stirred for 1 hour. Keeping the temperature below -5C, 110 ml of 25percent aqueous ammonia solution was added dropwise and the mixture was stirred for 2 hours at room temperature. The reaction mixture was poured into 270 ml of saturated ammonium chloride solution. After separation the aqueous layer was extracted with 2x 50 mL of [TETRAHYDROFURANE.] The combined organic solution was dried over sodium sulphate and evaporated. On addition of diethyl ether 21,19 g (59 percent) of the above product crystallized.
Reference: [1] Chemical and Pharmaceutical Bulletin, 2006, vol. 54, # 12, p. 1709 - 1714
[2] Patent: EP2246347, 2010, A1, . Location in patent: Page/Page column 39
[3] Patent: WO2003/106456, 2003, A2, . Location in patent: Page 28
[4] Bioorganic and Medicinal Chemistry, 2004, vol. 12, # 23, p. 6053 - 6061
  • 25
  • [ 1336-21-6 ]
  • [ 541-41-3 ]
  • [ 13726-69-7 ]
  • [ 109384-24-9 ]
Reference: [1] Patent: US5104867, 1992, A,
  • 26
  • [ 13726-69-7 ]
  • [ 80029-43-2 ]
  • [ 109384-24-9 ]
Reference: [1] Patent: EP1333025, 2003, A1,
  • 27
  • [ 13726-69-7 ]
  • [ 401564-36-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 9, p. 2618 - 2621
[2] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 11, p. 3662 - 3671
[3] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 16, p. 5033 - 5041
[4] Patent: WO2015/19238, 2015, A1,
[5] Patent: WO2016/79699, 2016, A1,
  • 28
  • [ 1315326-77-2 ]
  • [ 13726-69-7 ]
  • [ 1315326-78-3 ]
Reference: [1] Patent: US2011/178107, 2011, A1, . Location in patent: Page/Page column 69; 70
  • 29
  • [ 13726-69-7 ]
  • [ 1448189-80-7 ]
Reference: [1] Patent: WO2014/108452, 2014, A1,
[2] Patent: WO2015/867, 2015, A1,
[3] Patent: US2016/45607, 2016, A1,
[4] Patent: US2016/45607, 2016, A1,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 13726-69-7 ]

Asunaprevir Related Intermediates

Chemical Structure| 24188-74-7

[ 24188-74-7 ]

7-Chloroisoquinolin-1-ol

Chemical Structure| 159622-10-3

[ 159622-10-3 ]

(1R,2S)-1-((tert-Butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylic acid

Chemical Structure| 259217-95-3

[ 259217-95-3 ]

(1R,2S)-Ethyl 1-((tert-butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylate

Chemical Structure| 62965-35-9

[ 62965-35-9 ]

Boc-Tle-OH

Chemical Structure| 630423-36-8

[ 630423-36-8 ]

1,7-Dichloro-4-methoxyisoquinoline

Related Functional Groups of
[ 13726-69-7 ]

Amino Acid Derivatives

Chemical Structure| 135042-17-0

[ 135042-17-0 ]

(2R,4S)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate

Similarity: 0.95

Chemical Structure| 102195-79-9

[ 102195-79-9 ]

(2S,4S)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate

Similarity: 0.95

Chemical Structure|

[ ]

Similarity: 0.95

Chemical Structure| 114676-69-6

[ 114676-69-6 ]

(2R,4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate

Similarity: 0.95

Chemical Structure| 917835-93-9

[ 917835-93-9 ]

1-(tert-Butoxycarbonyl)-4-hydroxypiperidine-2-carboxylic acid

Similarity: 0.95